Clinical Trial Update: A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy [Phase 1]

View source ↗

Summary

A Phase 1 trial update describes a feasibility study using immune recall to boost responses to checkpoint inhibitors in melanoma, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Duke University | Conditions: Melanoma | Phase 1 | Status: RECRUITING